CNSX:TRULPharmaceuticals
How Investors Are Reacting To Trulieve Cannabis (CNSX:TRUL) Seeking Expedited DEA Schedule III Registration
In April 2026, Trulieve Cannabis Corp. filed applications with the U.S. Drug Enforcement Administration to register certain state-licensed medical marijuana operations under the new expedited Schedule III pathway, which deems licenses approved within 60 days unless the agency objects.
This move could help Trulieve transition qualifying medical marijuana activities into a federally regulated Schedule III framework, potentially reshaping how its operations interact with U.S. drug policy and...